Maravai LifeSciences Holdings, Inc. (MRVI) stock
Close on Nov 17, 2026Market cap $1.89BP/E –Yield –
Earnings
Maravai LifeSciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Maravai LifeSciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026Expected | – | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026after the close | $51.40M | +8.4% | -$0.08 | -$0.02 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026after the close | $65.80M | +40.3% | -$0.02 | $0.01 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 25, 2026after the close | $49.90M | – | -$0.24 | -$0.04 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025after the close | $41.60M | -36.2% | -$0.18 | -$0.08 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 11, 2025after the close | $47.40M | -35.4% | -$0.27 | -$0.08 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 12, 2025after the close | $46.90M | -26.9% | -$0.21 | -$0.08 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 25, 2025after the close | – | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024after the close | $65.20M | -2.5% | -$0.70 | -$0.02 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 7, 2024after the close | $73.40M | +6.5% | -$0.05 | $0.00 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024after the close | $64.20M | -18.7% | -$0.09 | -$0.02 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 22, 2024after the close | $74.10M | -63.8% | -$0.80 | $0.01 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023after the close | $66.90M | -65.0% | -$0.05 | -$0.01 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 7, 2023after the close | $68.90M | -71.6% | -$0.05 | $0.00 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 8, 2023after the close | $79.00M | -67.7% | $0.00 | $0.03 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 22, 2023after the close | $204.70M | -10.4% | $0.28 | $0.35 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 2, 2022after the close | $191.30M | -6.6% | $0.34 | $0.37 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022after the close | $242.70M | – | $0.53 | $0.54 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022after the close | $244.30M | – | $0.50 | $0.54 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 23, 2022after the close | $228.40M | – | $0.42 | $0.45 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021after the close | $204.80M | – | $0.45 | $0.44 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 10, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 5, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 2, 2021after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Maravai LifeSciences's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Revenue | FY2026 | $205.00M – $215.00M | $205.00M – $215.00M | Reaffirmed | Aug 6, 2026 |
| Adjusted EBITDA (non-GAAP)non-GAAP | FY2026 | $33.00M – $35.00M | $30.00M – $32.00M | Raised | Aug 6, 2026 |
Guidance vs results
The last range Maravai LifeSciences gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $185.00M | $185.80MΣ4Q | Above range |
Guidance history
Every forecast Maravai LifeSciences put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 6, 2026 | Adjusted EBITDA (non-GAAP) | FY2026 | $33.00M – $35.00M | Raised |
| Aug 6, 2026 | Revenue | FY2026 | $205.00M – $215.00M | Reaffirmed |
| May 7, 2026 | Adjusted EBITDA (non-GAAP) | FY2026 | $30.00M – $32.00M | Raised |
| May 7, 2026 | Revenue | FY2026 | $205.00M – $215.00M | Raised |
| Feb 25, 2026 | Adjusted EBITDA (non-GAAP) | FY2026 | $18.00M – $20.00M | New |
| Feb 25, 2026 | Revenue | FY2026 | $200.00M – $210.00M | New |
| Nov 6, 2025 | Revenue | FY2025 | $185.00M | New |
| May 12, 2025 | Revenue | FY2025 | $185.00M – $205.00M | New |
| Feb 25, 2025 | revenue | FY2024 | $255.00M – $265.00M | Reaffirmed |
| Nov 7, 2024 | Adjusted EBITDA (non-GAAP) margins | FY2024 | 16% – 18% | Lowered |
| Nov 7, 2024 | revenue | FY2024 | $255.00M – $265.00M | Lowered |
| Aug 7, 2024 | Adjusted EBITDA (non-GAAP) margins | FY2024 | 20% – 22% | Lowered |
| Aug 7, 2024 | Revenue | FY2024 | $265.00M – $285.00M | Reaffirmed |
| May 8, 2024 | Adjusted EBITDA (non-GAAP) margins | FY2024 | 23% – 25% | New |
| May 8, 2024 | Revenue expectations | FY2024 | $265.00M – $285.00M | Reaffirmed |
| Feb 22, 2024 | Adjusted EBITDA (non-GAAP) margins | FY2024 | 23% – 25% | New |
| Feb 22, 2024 | Revenue | FY2024 | $265.00M – $285.00M | New |
| Nov 7, 2023 | Adjusted EBITDA | FY2023 | $55.00M – $60.00M | Lowered |
| Nov 7, 2023 | Adjusted fully diluted EPS | FY2023 | -$0.01 – $0.01 | Lowered |
| Nov 7, 2023 | interest expense | FY2023 | $16.00M – $18.00M | Lowered |
| Nov 7, 2023 | depreciation and amortization | FY2023 | $40.00M – $42.00M | Raised |
| Nov 7, 2023 | stock-based compensation | FY2023 | $34.00M – $36.00M | Lowered |
| Nov 7, 2023 | total revenue | FY2023 | $275.00M – $285.00M | Lowered |
| Aug 7, 2023 | Adjusted EBITDA (non-GAAP) | FY2023 | $70.00M – $80.00M | Lowered |
| Aug 7, 2023 | Adjusted fully diluted EPS (non-GAAP) | FY2023 | $0.04 – $0.08 | Lowered |
| Aug 7, 2023 | interest expense | FY2023 | $16.00M – $18.00M | Lowered |
| Aug 7, 2023 | depreciation and amortization | FY2023 | $38.00M – $40.00M | Raised |
| Aug 7, 2023 | stock-based compensation | FY2023 | $34.00M – $38.00M | Lowered |
| Aug 7, 2023 | Total revenue | FY2023 | $300.00M – $325.00M | Lowered |
| May 8, 2023 | Adjusted EBITDA (non-GAAP) | FY2023 | $155.00M – $175.00M | Lowered |
| May 8, 2023 | Adjusted fully diluted EPS (non-GAAP) | FY2023 | $0.27 – $0.33 | Lowered |
| May 8, 2023 | interest expense | FY2023 | $18.00M – $22.00M | New |
| May 8, 2023 | depreciation and amortization | FY2023 | $38.00M – $42.00M | Raised |
| May 8, 2023 | stock-based compensation | FY2023 | $34.00M – $38.00M | Lowered |
| May 8, 2023 | Total revenue | FY2023 | $400.00M – $440.00M | Lowered |
| Feb 22, 2023 | Adjusted EBITDA | FY2023 | $170.00M – $190.00M | New |
| Feb 22, 2023 | Adjusted fully diluted EPS (non-GAAP) | FY2023 | $0.32 – $0.38 | New |
| Feb 22, 2023 | Total revenue | FY2023 | $420.00M – $460.00M | New |
| Nov 2, 2022 | Adjusted EBITDA | FY2022 | $650.00M – $660.00M | Raised |
| Nov 2, 2022 | Adjusted fully diluted EPS | FY2022 | $1.76 – $1.80 | Raised |
| Nov 2, 2022 | Total revenue | FY2022 | $880.00M – $890.00M | Raised |
| Aug 4, 2022 | Adjusted EBITDA | FY2022 | $640.00M – $660.00M | Lowered |
| Aug 4, 2022 | Adjusted fully diluted EPS | FY2022 | $1.70 – $1.80 | Lowered |
| Aug 4, 2022 | Total revenue | FY2022 | $880.00M – $910.00M | Lowered |
| May 5, 2022 | Adjusted EBITDA | FY2022 | $650.00M – $690.00M | Raised |
| May 5, 2022 | Adjusted fully diluted EPS | FY2022 | $1.74 – $1.90 | Raised |
| May 5, 2022 | total revenue | FY2022 | $920.00M – $960.00M | Reaffirmed |
| Feb 23, 2022 | Adjusted EBITDA (non-GAAP) | FY2022 | $630.00M – $670.00M | New |
| Feb 23, 2022 | Adjusted fully diluted EPS (non-GAAP) | FY2022 | $1.70 – $1.84 | New |
| Feb 23, 2022 | Total revenue | FY2022 | $920.00M – $960.00M | New |
| Nov 10, 2021 | Adjusted EBITDA (non-GAAP) | FY2021 | $570.00M – $575.00M | New |
| Nov 10, 2021 | Adjusted fully diluted EPS (non-GAAP) | FY2021 | $1.48 – $1.52 | New |
| Nov 10, 2021 | interest expense | FY2021 | $34.00M – $35.00M | New |
| Nov 10, 2021 | depreciation and amortization | FY2021 | $28.00M – $29.00M | Lowered |
| Nov 10, 2021 | equity-based compensation | FY2021 | $11.00M – $12.00M | Lowered |
| Nov 10, 2021 | Total revenue | FY2021 | $770.00M – $780.00M | New |
| Nov 10, 2021 | Total revenue | FY2022 | $840.00M – $880.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Maravai LifeSciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
- Update
- Update
- Results
- Results
- Results
- Results
- Update
- Results
- Results
See a number that looks wrong?